查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
異位性皮膚炎市場:KOL的洞察
市場調查報告書
商品編碼
1789646

異位性皮膚炎市場:KOL的洞察

KOL Insight - Atopic Dermatitis
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告基於對美國和歐洲領先的皮膚科關鍵人事官 (KOL) 的訪談，對中度至重度異位性皮膚炎治療格局的演變進行了深入的定性分析。本報告探討了專家對新上市和在研療法的看法，重點關注 Evgris 的崛起、對 Nemrubio 的不同看法，以及安麗單抗與其他新興療法的相對定位。專家洞察包括當前的處方趨勢、重要的臨床考慮因素以及新數據發布後的市場變化。

關鍵問題解答：

  • 1.Dupixent 目前在異位性皮膚炎的應用情況如何？
  • 2.近期上市的最有前景的異位性皮膚炎療法有哪些？它們的作用機轉是什麼？
  • 3.哪些在研療法預計會影響異位性皮膚炎治療？
  • 4.影響當前和未來處方趨勢的關鍵臨床試驗。
  • 5.與現有療法相比，專家如何看待新興療法的療效和安全性？
  • 6.哪些因素正在推動或限制新型異位性皮膚炎藥物的採用？
  • 7.KOL 預計中度至重度異位性皮膚炎的治療方案將如何發展？
  • 8.中度至重度異位性皮膚炎的治療中有哪些未滿足的需求？
  • 9.患者的特徵和嚴重程度如何影響全身性治療的選擇？
  • 10.預計新療法將對目前異位性皮膚炎的市場領導者產生哪些影響？

主要品牌

  • Dupixent
  • Evglis
  • Adbry/Adtraza
  • Cybainco
  • Rimboq
  • Nemrubio

部分參與品牌名單專家

  • 加州大學舊金山分校皮膚病學教授
  • 北卡羅來納州溫斯頓-塞勒姆維克森林大學醫學院皮膚病學、病理學和公共衛生科學教授
  • 路易斯維爾大學醫學院皮膚病學臨床教授
  • 義大利維羅納大學皮膚病學教授
  • 法國圖盧茲保羅‧薩巴蒂爾大學皮膚病學教授
  • 索爾福德皇家NHS基金會皮膚病學教授兼顧問皮膚科醫生

方法：

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病領域的當前和未來治療前景。我們根據嚴格的標準精心挑選關鍵意見領袖 (KOL)，這些標準包括全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都附有精心設計的討論指南。這些指南由我們與關鍵意見領袖合作開發，並由行業專家進行同行評審，確保問題全面且與當前市場動態相關。每份報告發布後，我們會持續 12 個月的市場監測，及時提供關鍵意見領袖對重要新聞事件、市場變化和市場發展的更新。

我們報告的特點

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢並有效解決複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家專訪和數據，結合持續的市場監測，確保您全面洞察市場動態。我們的報告涵蓋 40 多個活躍疾病領域，包含 KOL 洞察和定量醫生調查等醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

This report provides an in-depth qualitative analysis of the evolving treatment landscape for moderate-to-severe atopic dermatitis, based on interviews with leading dermatology KOLs across the US and Europe. It examines expert perceptions of newly launched and pipeline therapies, with particular attention to the rise in Ebglyss, mixed views on Nemluvio, and how amlitelimab is positioned relative to other emerging agents. Gain expert insights on current prescribing trends, key clinical considerations, and how the market may shift as new data become available.

Key Questions Answered:

  • 1. How is Dupixent currently used in atopic dermatitis, and how might its prescribing change in the future?
  • 2. Which recently launched therapies and mechanisms of action are most promising for atopic dermatitis?
  • 3. Which pipeline products are expected to impact the atopic dermatitis treatment landscape?
  • 4. What are the key clinical trials influencing current and future prescribing trends?
  • 5. How do experts view the efficacy and safety of new and emerging therapies compared to established treatments?
  • 6. What factors are driving or limiting the uptake of new atopic dermatitis therapies?
  • 7. How do KOLs expect the treatment algorithm for moderate-to-severe atopic dermatitis to evolve?
  • 8. What are the main unmet needs in the management of moderate-to-severe atopic dermatitis?
  • 9. How do patient characteristics and disease severity influence systemic therapy selection?
  • 10. What is the anticipated impact of new therapies on current market leaders in atopic dermatitis?

Key Brands:

  • Dupixent
  • Ebglyss
  • Adbry/Adtralza
  • Cibinqo
  • Rinvoq
  • Nemluvio

Partial List of Participating Experts:

  • Professor of Dermatology at the University of California San Francisco, San Francisco, CA.
  • Professor of Dermatology, Pathology, and Public Health Sciences at Wake Forest University School of Medicine, Winston-Salem, NC.
  • Clinical Professor of Dermatology at the University of Louisville School of Medicine, Louisville, KY.
  • Professor of Dermatology at the University of Verona, Verona, Italy.
  • Professor of Dermatology at Paul Sabatier University, Toulouse, France.
  • Professor of Dermatology and Consultant Dermatologist at Salford Royal NHS Foundation Trust; and Director of the Dermatopharmacology Unit at the University of Manchester, Manchester, UK.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.